OBJECTIVE: To examine blood transfusion practices and develop a standardized bundle of interventions to address the high rate of perioperative red blood cell transfusion among patients with ovarian and endometrial cancer. METHODS: This was a retrospective cohort study. Our primary aim was to determine whether an implemented bundled intervention was associated with a reduction in perioperative red blood cell transfusions among cases of laparotomy for cancer. Secondary aims included comparing perioperative demographic, surgical, complication, and cost data. Interventions included blood transfusion practice standardization using American Society of Anesthesiologists guidelines, an intraoperative hemostasis checklist, standardized intraoperative fluid status communication, and evidence-based use of tranexamic acid. Prospective data from women undergoing laparotomy for ovarian or endometrial cancer from September 28, 2015, to May 31, 2016, defined the study cohort and were compared with historical controls (September 1, 2014, to September 25, 2015). Outcomes were compared in the full unadjusted cohorts and in propensity-matched cohorts. RESULTS: In the intervention and historical cohorts, respectively, 89 and 184 women underwent laparotomy for ovarian cancer (n=74 and 152) or advanced endometrial cancer (n=15 and 32). Tranexamic acid was administered in 54 (60.7%) patients. The perioperative transfusion rate was lower for the intervention group compared with historical controls (18.0% [16/89] vs 41.3% [76/184], P<.001), a 56.4% reduction. This improvement in the intervention group remained significant after propensity matching (16.2% [13/80] vs 36.2% [29/80], P=.004). The hospital readmission rate was also lower for the intervention group compared with historical controls (1.1% [1/89] vs 12.5% [23/184], P=.002); however, this improvement did not attain statistical significance after propensity matching (1.2% [1/80] vs 7.5% [6/80], P=.12). Cost analysis demonstrated that this intervention was cost-neutral during index hospitalization plus 30-day follow-up. CONCLUSION: Application of a standardized bundle of evidence-based interventions was associated with reduced blood use in our gynecologic oncology practice.
OBJECTIVE: To examine blood transfusion practices and develop a standardized bundle of interventions to address the high rate of perioperative red blood cell transfusion among patients with ovarian and endometrial cancer. METHODS: This was a retrospective cohort study. Our primary aim was to determine whether an implemented bundled intervention was associated with a reduction in perioperative red blood cell transfusions among cases of laparotomy for cancer. Secondary aims included comparing perioperative demographic, surgical, complication, and cost data. Interventions included blood transfusion practice standardization using American Society of Anesthesiologists guidelines, an intraoperative hemostasis checklist, standardized intraoperative fluid status communication, and evidence-based use of tranexamic acid. Prospective data from women undergoing laparotomy for ovarian or endometrial cancer from September 28, 2015, to May 31, 2016, defined the study cohort and were compared with historical controls (September 1, 2014, to September 25, 2015). Outcomes were compared in the full unadjusted cohorts and in propensity-matched cohorts. RESULTS: In the intervention and historical cohorts, respectively, 89 and 184 women underwent laparotomy for ovarian cancer (n=74 and 152) or advanced endometrial cancer (n=15 and 32). Tranexamic acid was administered in 54 (60.7%) patients. The perioperative transfusion rate was lower for the intervention group compared with historical controls (18.0% [16/89] vs 41.3% [76/184], P<.001), a 56.4% reduction. This improvement in the intervention group remained significant after propensity matching (16.2% [13/80] vs 36.2% [29/80], P=.004). The hospital readmission rate was also lower for the intervention group compared with historical controls (1.1% [1/89] vs 12.5% [23/184], P=.002); however, this improvement did not attain statistical significance after propensity matching (1.2% [1/80] vs 7.5% [6/80], P=.12). Cost analysis demonstrated that this intervention was cost-neutral during index hospitalization plus 30-day follow-up. CONCLUSION: Application of a standardized bundle of evidence-based interventions was associated with reduced blood use in our gynecologic oncology practice.
Authors: Megan P Johnson; Sharon J Kim; Carrie L Langstraat; Sneha Jain; Elizabeth B Habermann; Jean E Wentink; Pamela L Grubbs; Sharon A Nehring; Amy L Weaver; Michaela E McGree; Robert R Cima; Sean C Dowdy; Jamie N Bakkum-Gamez Journal: Obstet Gynecol Date: 2016-06 Impact factor: 7.661
Authors: R P McGehee; M K Dodson; J L Moore; F S Morrison; J D Bass; P Burrow; J C Morrison Journal: Int J Gynaecol Obstet Date: 1994-07 Impact factor: 3.561
Authors: Yoan K Kagoma; Mark A Crowther; James Douketis; Mohit Bhandari; John Eikelboom; Wendy Lim Journal: Thromb Res Date: 2008-11-12 Impact factor: 3.944
Authors: Sue L Visscher; James M Naessens; Barbara P Yawn; Megan S Reinalda; Stephanie S Anderson; Bijan J Borah Journal: BMC Health Serv Res Date: 2017-06-12 Impact factor: 2.655
Authors: Edward J Tanner; Olga T Filippova; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Oliver Zivanovic; Mary Fischer; Dennis S Chi Journal: Gynecol Oncol Date: 2018-10-16 Impact factor: 5.482
Authors: Lauren S Prescott; Jolyn S Taylor; Ahmed Enbaya; Claire A Marten; Keith N Myers; Larissa A Meyer; Pedro T Ramirez; Charles F Levenback; Diane C Bodurka; Kathleen M Schmeler Journal: Gynecol Oncol Date: 2019-03-11 Impact factor: 5.482
Authors: Deepa M Narasimhulu; Aneesa Thannickal; Amanika Kumar; Amy L Weaver; Michaela E McGree; Carrie L Langstraat; William A Cliby Journal: Gynecol Oncol Date: 2020-12-31 Impact factor: 5.482